Diseases & Conditions
Grants & Contracts
News & Events
February 24, 2023
As the latest research on HIV and other infectious diseases continued to be presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with Dr. Carl Dieffenbach about some of the highlights. Dr. Dieffenbach is the Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Disease. He shared updates about some research on long-acting HIV prevention and treatment and COVID treatment and prevention. He also discussed news of another reported case of HIV cure. Watch our conversation with Dr. Dieffenbach below:
January 19, 2023
Fatal familial insomnia (FFI) is a little-known yet horrific disease in which people die from lack of sleep. In a new study, NIAID scientists developed a cerebral organoid model to study the exact protein mutation that causes FFI.
January 18, 2023
A team of NIAID-led researchers has identified a mechanism in mice in which the immune system and commensal bacteria help repair damaged sensory neurons within the skin. They hope their findings could lead to therapies that stimulate recovery in people following skin injury and limit damage from chemotherapy and chronic diseases.
January 10, 2023
Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.
December 08, 2022
As scientists learn more about SARS-CoV-2 and its infection tactics, nasal vaccines appear to be a promising response.
December 06, 2022
Developing a vaccine capable of fighting a diverse group of coronaviruses and viral variants remains a priority for NIAID, which NIAID has awarded an additional $26.1 million for four additional “pan-coronavirus” vaccine grant awards,
October 20, 2022
To reduce the spread of HIV infection, the World Health Organization (WHO) recommends pre-exposure prophylaxis (PrEP) in populations with an annual HIV infection incidence greater than 3%. Given that the annual HIV incidence in Uganda is estimated at 0.40% (0.46% among females and 0.35% among males), there are people who may have a higher HIV risk and may benefit from PrEP but are not targeted for services.
October 17, 2022
The National Institute of Allergy and Infectious Diseases, a part of NIH, stands with the scientific community in recognizing October as Eczema Awareness Month and acknowledging the need for continued research into possible cures and therapeutics.
August 22, 2022
The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology
August 19, 2022
In recognition of World Mosquito Day on Saturday, Aug. 20, NIAID interviewed grantee Courtney Murdock, Ph.D., of Cornell University to learn more about her team’s research on the relationship between the environment and mosquito-borne diseases. Read how monitoring temperature, humidity – and the need for more data – will affect whether scientists can make a significant public health impact for diseases like malaria, dengue and Zika.
August 17, 2022
An investigational typhoid vaccine containing a component developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine in June.
July 13, 2022
For decades, scientists have wondered how different strains of prions can propagate when they do not carry their own genes with them as they move from host to host. A new study from NIAID researchers and colleagues reveals how differences in the folding of the primary protein of prions (PrP) can help determine the distinct characteristics of prion strains.
June 07, 2022
NIAID investigators recently published initial results from a study seeking to characterize and better understand persistent symptoms some people experience after having COVID. These persistent symptoms, often referred to as “long COVID,” can sometimes be debilitating, and their cause is currently unknown. This single-site study is part of a larger research effort across multiple institutes at NIH and NIH-funded institutions to understand, prevent, and treat long-term health effects related to COVID-19.
May 19, 2022
The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.
May 18, 2022
Today marks the 25th anniversary of the first HIV Vaccine Awareness Day. Although tremendous progress has been made over the past several decades in HIV treatment and prevention, the development of a safe, effective, and durably protective vaccine to prevent HIV infection has, unfortunately, remained elusive. On this commemorative day, NIAID acknowledges the disappointments of the past while optimistically looking ahead to what’s next in HIV vaccine development.
May 11, 2022
NIAID researchers designed a ferritin nanoparticle flu vaccine and tested it in people with and without immunological experience of the flu virus that caused the 1957 pandemic. The experimental vaccine prompted immune responses that suggested this kind of vaccine could provide long-lasting protection against many flu subtypes.
March 31, 2022
When the next SARS-CoV-2 variant of concern emerges in the world, NIAID will call on SAVE – its version of The Avengers – to quickly react and protect people. SAVE (SARS-CoV-2 Assessment of Viral Evolution) members assess whether mutations in variants can affect virus transmission, severity and immunity; test vaccines and therapeutics; and guide responses.
February 18, 2022
A comprehensive analysis evaluating immune responses in children with SARS-CoV-2 infection and in those with a rare post-infection inflammatory syndrome called MIS-C has revealed distinct immunopathological signatures associated with each condition.
January 28, 2022
January 30, 2022, marks the third World Neglected Tropical Diseases (NTDs) Day, presenting an opportunity to reflect both on the continuing burden imposed by these diseases and the significant progress made to curtail them. NTDs comprise viral, bacterial, fungal and parasitic diseases that, despite their various causes, have in common their substantial health, social and economic impacts, especially on marginalized populations living in tropical and subtropical countries.
December 10, 2021
A new study in mice from NIAID scientists now shows that toxins from Staphylococcus aureus alarm the immune system hours earlier than previously known.
November 24, 2021
Antimicrobials such as antibiotics, antivirals, and antifungal drugs are crucial tools in the fight against disease-causing microbes. However, resistance of microbes to these life-saving medicines is a growing global public health dilemma. In fact, the Centers for Disease Control and Prevention (CDC) reports that more than 2.8 million infections and over 35,000 deaths are caused by antibiotic-resistant pathogens in the US annually.
November 24, 2021
A new study from NIAID's Intramural research program provides an update on research into using a probiotic to treat bacterial gut infections.
November 17, 2021
NIAID launched the Centers for Research in Emerging Infectious Diseases Network (CREID Network) in August 2020. One key component of the CREID Network is the Pilot Research Program, which provides financial support and mentorship opportunities to early-career researchers. The program focuses on training the next generation of emerging infectious disease researchers to build expertise and research capacity around the world.
November 04, 2021
The National Institutes of Health has awarded approximately $16 million to support implementation science research to advance the goals of Ending the HIV Epidemic in the U.S. (EHE), which aims to reduce new HIV infections in the United States by at least 90% by 2030.
October 29, 2021
Plasmodium falciparum, the parasite that causes malaria, creates a significant burden of morbidity and mortality around the world. In pregnant women, P falciparum- infected red blood cells (iRBCs) collect in vascular spaces of the placenta by binding to chondroitin sulfate A (CSA). This sequestration of iRBCs can result in inflammatory responses, which can lead to many adverse pregnancy outcomes such as severe maternal anemia, fetal growth retardation, premature delivery, maternal and/or perinatal mortality.